Sore Throat News and Research

RSS

Views on giving flu shot to younger children

It's a common question parents ask themselves this time of year: Does my child really need a flu shot? Though the flu may seem harmless, the truth is on average 20,000 children age 5 and younger are hospitalized due to flu symptoms each year.

10 Oct 2014

State highlights: N.C. lawmakers still talking about Medicaid revamp; changes to La. health plan for state workers stir controversy

Legislators who couldn't agree this year on how to overhaul North Carolina's Medicaid program plan to spend more time talking about the issue before the General Assembly reconvenes early next year. A legislative oversight panel subcommittee charged with examining Medicaid reform and reorganization scheduled its first meeting Wednesday. Another oversight panel also examining Medicaid governance held its first meeting this month. The House and Senate approved differing versions of legislation to change how Medicaid pays for medical expenses by shifting risk from the state to either medical provider networks or private managed-care companies (9/24).

26 Sep 2014

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide.

12 Aug 2014

Computational biologists develop program for easy diagnosis of hereditary illnesses

In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.

29 Jul 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Patients kept in the dark on costs of tests, treatments

The CT Mirror examines the difficulties patients face when trying to comparison shop or simply figure out how much they might have to spend on medical treatments.

27 Jun 2014

Summer offers ideal opportunity to get tonsil removal

Pool pass, sports camp, visiting relatives and getting tonsils removed are all normal activities for children during the summer months.

25 Jun 2014

Verizon advances patient care with new mobile health product

Verizon today (June 25) announced the immediate availability of Verizon Virtual Visits, which provides an easy, convenient and cost-effective way for patients to be seen remotely by a clinician for a cold, flu, sore throat or other simple, acute conditions, via video on their smartphone, tablet or computer.

25 Jun 2014

Culture-based tests can help in accurate diagnosis of sore throats

Clinical guidelines conflict on testing teens and adults whose symptoms point to a possible strep throat.

29 May 2014

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014.

19 May 2014

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),

16 May 2014

Virtual doctors visits await regulation, grow in popularity

And recommendations on digital privacy protections for electronic health records could come as early as June.

12 May 2014

First Edition: May 9, 2014

Today's headlines include highlights from the first Senate confirmation hearing for Sylvia Mathews Burwell, President Barack Obama's pick for Health and Human Services Secretary.

9 May 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Oral and oropharyngeal cancer (cancer of the mouth and upper throat) collectively kill nearly one person every hour of every day of the year.

27 Mar 2014

Study shows only 23% of seasonal and pandemic flu caused symptoms

Around 1 in 5 of the population were infected in both recent outbreaks of seasonal flu and the 2009 H1N1 influenza pandemic, but just 23% of these infections caused symptoms, and only 17% of people were ill enough to consult their doctor.

17 Mar 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold.

3 Feb 2014

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013